Antibodies to a synthetic peptide from the preS 120-145 region of the hepatitis B virus envelope are virus neutralizing.
Studies with synthetic peptides have provided evidence for the presence of preS coded sequences in the envelope (env) proteins of hepatitis B virus (HBV) and indicated that these sequences are involved in the specific attachment of HBV to liver cells. Scanning of the preS sequence for immunodominant continuous epitopes identifies the sequence within residues preS (120-145) as the most immunogenic in eliciting antibodies recognizing HBV and as the most efficiently binding antibodies from sera of rabbits and humans immunized with HBV env proteins. To assess the potential of preS (120-145) as a synthetic vaccine against hepatitis B, in vitro neutralization of the virus by rabbit antiserum to the peptide was assayed in chimpanzees. The animals, subsequently proven to be susceptible to HBV infection, did not develop hepatitis B as judged by negative serological tests for HBV-associated antigens and antibodies and by normal serum alanine aminotransferase levels and normal liver biopsies. These results establish the role of preS domains in the process of virus neutralization and the potential of synthetic preS analogues for hepatitis B vaccination.
A R
AR
Neurath
S B
SB
Kent
K
K
Parker
A M
AM
Prince
N
N
Strick
B
B
Brotman
P
P
Sproul
D000818:Animals; D000939:Epitopes / Q000276:immunology; D006509:Hepatitis B / Q000517:prevention & control; D006510:Hepatitis B Antibodies / Q000276:immunology*; D006511:Hepatitis B Antigens / Q000276:immunology*; D006515:Hepatitis B virus / Q000276:immunology*; D009500:Neutralization Tests; D002679:Pan troglodytes; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology; D014759:Viral Envelope Proteins / Q000276:immunology*; D014761:Viral Hepatitis Vaccines / Q000276:immunology
D000939:Epitopes; D006510:Hepatitis B Antibodies; D006511:Hepatitis B Antigens; D010455:Peptides; D014759:Viral Envelope Proteins; D014761:Viral Hepatitis Vaccines